Research and Clinical Trials

Title  
Chimerix CMX001-351: An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Brief Description  
The primary objective of this intermediate-size, expanded access protocol is to provide patients with serious adenovirus infection or disease access to treatment with Brincidofovir.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Ill-Defined Sites
Status  
OPEN
Start Date  
10/25/2016
IRB Number  
00018806
Principal Investigator  
Huo, Jeffrey
Contact Name  
Tracy L Fukes

For More Information, Contact  Tracy  L, Fukes
Phone:  980-442-2310 Fax:    
Email:  tracy.fukes@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close